MetLife (MET) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
17 Jan, 2026Executive summary
Q3 net income rose to $1.3 billion ($1.81/share), up sharply from $422 million, driven by net derivative gains but offset by market risk benefit remeasurement losses.
Adjusted earnings were $1.4 billion ($1.95/share), down 8% year-over-year, with adjusted EPS nearly flat at -1% year-over-year.
Book value per share increased 33% to $39.02; book value excluding AOCI other than FCTA rose 3% to $54.72.
Return on equity was 20.2%; adjusted ROE excluding AOCI other than FCTA was 14.6%, above the full-year target.
Holding company cash and liquid assets stood at $4.5 billion, above the $3-4 billion target buffer.
Financial highlights
Total Q3 revenues were $18.4 billion, up from $15.9 billion; net investment income increased to $5.2 billion, with variable investment income declining due to lower private equity returns.
Premiums, fees, and other revenues were $12.5 billion, down 5% year-over-year; adjusted net investment income was $5.1 billion, up 2%.
Direct expense ratio improved to 11.7%, below the 12.3% annual target; overall expense ratio increased to 19.9%.
Share repurchases totaled $0.8 billion in Q3, with $2.8 billion repurchased YTD and $130 million in October.
Net investment gains and derivative gains improved, but market risk benefit remeasurement losses increased by $1.3 billion.
Outlook and guidance
Q4 RIS spreads expected to stabilize, with most interest rate caps now expired; direct expense ratio expected to rise in Q4 due to seasonality but full-year performance should beat the 12.3% target.
Management expects continued volatility from global economic and market conditions, including interest rate changes and inflation.
Asia full-year sales expected to be close to flat year-over-year; ROE expected to trend upwards as high-IRR businesses grow.
Quarterly target for variable investment income is $375 million, based on full-year 2024 guidance of ~$1.5 billion.
Management remains focused on expense discipline and capital deployment.
Latest events from MetLife
- Scale, technology, and disciplined growth drive strong earnings and market leadership.MET
47th Annual Raymond James Institutional Investor Conference4 Mar 2026 - New Frontier strategy delivers growth, efficiency, and global expansion, targeting double-digit EPS.MET
Bank of America Financial Services Conference 202610 Feb 2026 - Adjusted EPS up 10%, 16% ROE, and record AUM after major acquisition.MET
Q4 20255 Feb 2026 - Board, compensation, and auditor proposals passed; racial equity audit proposal rejected.MET
AGM 20243 Feb 2026 - Net income surged 146% with adjusted earnings up 9% and record Group Benefits results.MET
Q2 20242 Feb 2026 - Surpassed strategic goals and set sights on accelerated growth with the New Frontier plan.MET
2024 KBW Insurance Conference22 Jan 2026 - New Frontier targets double-digit EPS growth and 15–17% ROE, leveraging scale and global expansion.MET
Investor Day 202411 Jan 2026 - 2024 net income and ROE exceeded targets, with strong growth and capital metrics.MET
Q4 20248 Jan 2026 - New Frontier targets higher growth, stable margins, and global expansion with disciplined M&A.MET
Bank of America Securities Financial Services Conference8 Jan 2026